Impax Labs (NASDAQ:IPXL) stock price target dropped to $30 as recorded today by WallachBeth

August 10, 2016

Finance News

WallachBeth dropped the target stock price of Impax Labs (NASDAQ:IPXL) to $30, reporting a possible upside of 0.28%,

On 8/10/2016, RBC Capital released a statement for Impax Labs(NASDAQ:IPXL) of “Sector Perform” with a target price of $30. At the time, this indicated a possible upside of 0.28%.

Boasting a price of $23.43, Impax Labs (NASDAQ:IPXL) traded 3.50% lower on the day. With the last close down 30.68% relative to the two hundred day average, compared to the S&P 500 which has raised 0.00% over the same period. Impax Labs has been tracking to a 50-day moving average of $30.03 and two hundred day moving average of $32.62. 1,548,013 shares of the stock were exchanged, up from an avg. volume of 737,236

Recent Performance Chart:

Impax Labs (NASDAQ:IPXL)

With a market capitalization of $1.6B, Impax Labs has a 52 week low of $22.02 and a one-year high of $47.48 with a P/E ratio of 48.

Also covering Impax Labs’s stock price target, a total of 14 brokerages have issued a report on the stock. The consensus target stock price is $35.79 with two firms rating the company a strong buy, three firms rating the company a buy, seven analyts rating the stock a hold, three analysts rating the company to underperform, and lastly zero analystsrating the company as sell.

General Company Details For Impax Labs (NASDAQ:IPXL)

Impax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), as well as the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of various branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson’s disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, and indicated for the treatment of migraine headaches.

Comments are closed.